基因1b型慢性丙型肝炎患者血清铁蛋白水平与聚乙二醇干扰素抗病毒疗效的关系

游春芳; 周利民; 邓薇

doi:10.3969/j.issn.1001-5256.2017.09.016

基因1b型慢性丙型肝炎患者血清铁蛋白水平与聚乙二醇干扰素抗病毒疗效的关系

DOI: 10.3969/j.issn.1001-5256.2017.09.016

自贡市第一人民医院感染科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 1895
- HTML全文浏览量: 12
- PDF下载量: 390
- 被引次数: 0
出版历程
- 收稿日期: 2017-03-08
- 出版日期: 2017-09-20

Correlation between serum ferritin level and antiviral effect of pegylated interferon in chronic hepatitis C patients with genotype 1b

Department of Infectious Diseases, The First People's Hospital of Zigong

摘要

摘要: 目的探讨分析慢性丙型肝炎（CHC）患者血清铁蛋白（SF）水平与PEG-IFNα-2a疗效的相关性。方法选取2013年11月-2014年7月自贡市第一人民医院收治的85例CHC患者,均给予PEG-IFNα-2a,180μg,皮下注射,每周1次,同时联合利巴韦林口服1015 mg·kg-1·d-1,疗程48周,治疗结束后随访24周。在0周时检测SF,在0、4、12、24、48及72周检测HCV RNA以判断疗效。根据疗效分为快速病毒学应答组（RVR）、早期病毒学应答组（EVR）、持续病毒学应答组（SVR）、无应答组、复发组;根据SF水平分为高SF组（≥400 ng/ml）与低SF组（<400 ng/ml）。计量资料多组间比较采用方差分析,进一步两两比较采用SNKq检验;计数资料组间比较采用χ2检验;相关性分析采用Spearman秩相关性分析。结果 85例CHC患者中获得RVR 36例（42.35%）,EVR 70例（82.35%）,SVR 68例（80.00%）,无应答15例（17.65%）,复发...
- 肝炎,丙型,慢性 /
- 铁蛋白质类 /
- 干扰素α-2a /
- 治疗
Abstract: Objective To investigate the correlation between serum ferritin ( SF) level and antiviral effect of pegylated interferon-α-2a ( Peg-IFNα-2a) in chronic hepatitis C ( CHC) patients. Methods A total of 85 CHC patients who were admitted to The First People's Hospital of Zigong from November 2013 to July 2014 were enrolled and treated with subcutaneous injection of Peg-IFNα-2a 180 μg once a week combined with oral ribavirin 10-15 mg·kg-1·d-1. The course of treatment was 48 weeks and the patients were followed up for 24 weeks after the treatment ended. SF was measured at week 0, and HCV RNA was measured at weeks 0, 4, 12, 24, 48, and 72 to evaluate therapeutic outcome. According to the therapeutic outcome, the patients were divided into rapid virologic response ( RVR) group, early virologic response ( EVR) group, sustained virologic response ( SVR) group, no response group ( NR group) , and recurrence group; according to the SF level, the patients were divided into high-SF group ( ≥400 ng/ml) and low-SF group ( < 400 ng/ml) . An analysis of variance was used for comparison of continuous data between groups, and SNK-q test was used for comparison between any two groups; the chi-square test was used for comparison of categorical data between groups, and Spearman rank correlation was used for correlation analysis. Results Of all patients, 36 ( 42. 35%) achieved RVR, 70 ( 82. 35%) achieved EVR, 68 ( 80. 00%) achieved SVR, 15 ( 17. 65%) had no response, and 2 ( 2. 35%) experienced recurrence. The NR group and recurrence group had a significant increase in SF level, and the NR group had a significantly higher SF level than RVR group ( 1489. 15 ± 278. 21 ng/ml vs 398. 12 ± 252. 45 ng/ml, q = 10. 826, P < 0. 01) , EVR group ( 1489. 15 ± 278. 21 ng/ml vs 514. 85 ± 275. 64 ng/ml, q = 10. 151, P < 0. 01) , and SVR group ( 1489. 15 ± 278. 21 ng/ml vs486. 45 ± 251. 60 ng/ml, q = 10. 614, P < 0. 01) . SF level was negatively correlated with the therapeutic effect of PEG-IFN ( rs=-0. 688, P< 0. 001) . Compared with the high-SF group, the low-SF group had a significantly higher proportion of patients who achieved RVR ( 85. 29% vs13. 73%, P < 0. 001) , EVR ( 100% vs 70. 59%, P < 0. 001) , or SVR ( 100% vs 66. 67%, P < 0. 001) and a significantly lower proportion of patients who had no response ( 0 vs 29. 41%, P < 0. 001) . Conclusion In CHC patients, SF level before treatment is correlated with the antiviral effect of PEG-IFN, suggesting that SF level can predict the antiviral effect of PEG-IFN in CHC patients.
- hepatitis C, chronic /
- ferritins /
- interferon alfa-2a /
- therapy

HTML全文

参考文献(21)

[1]MA LY, ZHANG P, CHEN Q, et al.Changes in number of peripheral blood cells in patients with chronic hepatitis C after treated with interferon alpha 2b combined with ribavirin and their clinical significances[J].J Jilin Univ:Med Edit, 2015, 41 (3) :599-605. (in Chinese) 马琳媛, 张鹏, 陈倩, 等.干扰素α-2b联合利巴韦林治疗后慢性丙型肝炎患者外周血细胞数量的变化及其临床意义[J].吉林大学学报:医学版, 2015, 41 (3) :599-605.

[2]HE YM, HOU B.PEG-IFNα-2a and ribavirin for decompensated cirrhotic patients with hepatitis C after eliminating complications[J].Chin J Med Offic, 2017, 45 (4) :397-400. (in Chinese) 何妍梅, 侯波.聚乙二醇干扰素α-2a联合利巴韦林治疗失代偿期丙肝肝硬化并发症消除后患者临床观察[J].临床军医杂志, 2017, 45 (4) :397-400.

[3]WU CX.Influence of serum glutamic-pyruvic transaminase level and hepatitis C virus RNA quantification on therapeutic effect of interferon in chronic hepatitis C patients[J].China Foreign Med Treatment, 2013, 32 (34) :56-57. (in Chinese) 吴晨曦.慢性丙肝患者血清谷丙转氨酶水平、丙肝病毒RNA定量对干扰素疗效的影响分析[J].中外医疗, 2013, 32 (34) :56-57.

[4]DING L, ZHONG HY, SONG XB, et al.HCV genotype distribution in southwest China and its influence on patients’response to pegylated-interferonα-2a plus ribavirin therapy[J].J Sichuan Univ:Med Sci Edi, 2015, 46 (4) :573-577. (in Chinese) 丁柳, 钟慧钰, 宋兴勃, 等.四川人群丙肝病毒基因型分布及与抗病毒疗效的相关性[J].四川大学学报:医学版, 2015, 46 (4) :573-577.

[5]LUO Q, WU CX, LI CM, et al.Effect of IL-28B gene polymorphism and expression on antiviral therapy of patients with chronic hepatitis C[J].J Chongqing Med Univ, 2015, 40 (3) :335-339. (in Chinese) 罗旗, 伍春霞, 李成敏, 等.白细胞介素28B基因多态性以及表达水平对慢性丙型肝炎患者抗病毒治疗效果的影响研究[J].重庆医科大学学报, 2015, 40 (3) :335-339.

[6]KONG WL, YANG YL, XU HQ, et al.Relationship between liver function and virological response in patients with chronic hepatitis Cduring antiviral treatment[J].J Jilin Univ:Med Edit, 2016, 42 (1) :99-103. (in Chinese) 孔文丽, 杨以良, 徐洪芹, 等.慢性丙型肝炎患者抗病毒治疗中肝功能与病毒学应答的关系[J].吉林大学:医学版, 2016, 42 (1) :99-103.

[7]DISTANTE S, BJORO K, HELLUM KB, et al.Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection[J].Liver, 2002, 22 (3) :269-275.

[8]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[9]WEI L.Hepatitis C-clinical diagnosis and treatment manual[M].Beijing:Science Press, 2012. (in Chinese) 魏来.丙型肝炎-临床诊断与治疗手册[M].北京:科学出版社, 2012.

[10]MEI L, ZHU WD, ZHU YH, et al.Clinical effect of pegylated interferonα-2a combined with ribavirin in treatment of patients with genotype 1b chronic hepatitis C[J].Chin Hepatol, 2014, 19 (12) :952-954. (in Chinese) 梅蕾, 祝卫东, 朱跃红, 等.聚乙二醇干扰素α-2a联合利巴韦林治疗基因1b型慢性丙型肝炎临床观察[J].肝脏, 2014, 19 (12) :952-954.

[11]ZHAO JJ, LI J, LIU J, et al.Relationships of serum ferritin level, degree of liver inflammation and types in patients with liver disease[J].Shandong Med J, 2015, 55 (9) :21-23. (in Chinese) 赵晶晶, 李嘉, 刘洁, 等.肝病患者血清铁蛋白水平与肝脏炎症程度及肝病类型的关系[J].山东医药, 2015, 55 (9) :21-23.

[12]WU KK, WU C.Research advances in the value of serum ferritin measurement in chronic viral hepatitis[J/CD].Chin J Clinicians:Electronic Edition, 2013, 7 (12) :5568-5570. (in Chinese) 武抗抗, 吴超.血清铁蛋白水平在慢性病毒性肝炎中检测意义的研究进展[J/CD].中华临床医师杂志:电子版, 2013, 7 (12) :5568-5570.

[13]QIN Y, GUO YH, ZHANG Y, et al.Mechanism of iron metabolism disorder in patients with chronic hepatitis C[J].J Clin Hepatol, 2015, 31 (2) :291-294. (in Chinese) 秦源, 郭永红, 张颖, 等.慢性丙型肝炎铁代谢的失调机制[J].临床肝胆病杂志, 2015, 31 (2) :291-294.

[14]LANGE CM, KUTALIK Z, MORIKAWA K, et al.Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis Cpoorly responding to pegylated interferon-alpha and ribavirin therapy[J].Hepatology, 2012, 55 (4) :1038-1047.

[15]QI CW, CHEN Q, ZHANG XJ, et al.Research advances in abnormal iron metabolism in chronic hepatic C[J/CD].Chin J Liver Dis:Electronic Edition, 2015, 7 (2) :29-32. (in Chinese) 亓传旺, 陈倩, 张秀军, 等.慢性丙型肝炎铁代谢异常的研究进展[J/CD].中国肝脏病杂志:电子版, 2015, 7 (2) :29-32.

[16]HOFER H, OSTERREICHER C, JESSNER W, et al.Hepaticiron concentration does not predict response to standard and pegylatedIFN/ribavirin therapy in patients with chronic hepatitis C[J].JHepatol, 2004, 40 (6) :1018-1022.

[17]LADERO JM, LOPEZ-ALONSO G, DEVESA MJ, et al.Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C[J].Rev Esp Enterm Diq, 2009, 101 (1) :31-40.

[18]BARUT S, GUNAL O, ERKORKMAZ U.Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response[J].Scand J Infect Dis, 2012, 44 (10) :761-765.

[19]GONG L, JING Z, JIANG Y, et al.Relationship between the level of serum ferritin and the effects of peginterferon alfa-2a in treating chronic hepatitis C patients[J].Chin J New Drugs Clin Rem, 2007, 26 (1) :59-61. (in Chinese) 龚玲, 景钊, 江宇, 等.血清铁蛋白与培干扰素α-2a治疗慢性丙型肝炎疗效的关系[J].中国新药与临床杂志, 2007, 26 (1) :59-61.

[20]WALKER EM Jr, WALKER SM.Effects of iron overload on the immune system[J].Ann Clin Lab Sci, 2000, 30 (4) :354-365.

[21]LIN W, SI JL, ZHANG J, et al.Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C:a clinical analysis of160 patients of Uygur nationality or Han nationality[J].J Clin Hepatol, 2015, 31 (11) :1831-1836. (in Chinese) 林伟, 司建林, 张剑, 等.聚乙二醇干扰素α-2a联合利巴韦林治疗维吾尔族和汉族慢性丙型肝炎160例临床分析[J].临床肝胆病杂志, 2015, 31 (11) :1831-1836.

施引文献

资源附件(0)

访问统计